SUMMARY We report the cases of two adult patients in whom fulminant hepatitis developed after 17 and 103 days of ketoconazole administration. Histologic administration showed massive, predominantly centrilobular necrosis. Clinical manifestations of hypersensitivity and eosinophilia were absent in both patients, which suggests that ketoconazole hepatotoxicity is not mediated through an immunoallergic mechanism.
suggests that the liver lesion might be related, not to an immunoallergic mechanism, but rather to a direct or a reactive metabolite-mediated toxicity. This view is consistent with the relatively high prevalence of asymptomatic increase of serum ALT in patients receiving the drug1 and by the hepatic lesion observed in most of the dogs receiving high doses of ketoconazole. 12 Because of the risk of severe liver lesion, we recommend bimonthly or weekly measurements of serum ALT in patients receiving ketoconazole; monthly measurements are likely to be inadequate as our patient 2 died of fulminant hepatitis less than a month after the beginning of the administration of the drug. Ketoconazole administration must be immediately interrupted in patients with increased serum ALT; however, despite cessation of ketoconazole administration, liver function continued deteriorating, progressively in our patient 1 and rapidly in our patient 2.
An incidental finding in our patients was an increased gradient between wedged and free hepatic venous pressures, reflecting an increased portal venous pressure. A similar finding has been made in patients with fulminant viral hepatitis. 13 Portal hypertension is likely to be the consequence of disordered intrahepatic circulation resulting from massive necrosis, whether because of viral hepatitis or, as it was the case in our patient, to ketoconazoleinduced hepatitis. Portal hypertension is probably responsible for the development of ascites affecting our patients.
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